Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $227.4 million.

  • Autolus Therapeutics' Cash & Equivalents fell 86.89% to $86.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.1 million, marking a year-over-year decrease of 86.89%. This contributed to the annual value of $227.4 million for FY2024, which is 5.09% down from last year.
  • Per Autolus Therapeutics' latest filing, its Cash & Equivalents stood at $227.4 million for FY2024, which was down 5.09% from $239.6 million recorded in FY2023.
  • Autolus Therapeutics' Cash & Equivalents' 5-year high stood at $382.4 million during FY2022, with a 5-year trough of $227.4 million in FY2024.
  • Over the past 3 years, Autolus Therapeutics' median Cash & Equivalents value was $239.6 million (recorded in 2023), while the average stood at $283.1 million.
  • In the last 5 years, Autolus Therapeutics' Cash & Equivalents climbed by 23.23% in 2022 and then tumbled by 37.36% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Cash & Equivalents (Yearly) stood at $310.3 million in 2021, then grew by 23.23% to $382.4 million in 2022, then slumped by 37.36% to $239.6 million in 2023, then decreased by 5.09% to $227.4 million in 2024.